title: Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study.
abstract: 37 patients with disease progression after prior treatment for malignant lymphoma (27 low grade, 7 high grade and 3 Hodgkin's) were treated with oral trofosfamide daily. Most of these patients were heavily pretreated, with a median number of two regimens. Their median performance status was 1 (22 patients with 0-1 and 14 with 2-3). The overall response rate was 49% (18/37; 3/37 CRs and 15/37 (41%) PRs). Median time to progression (TTP) from start of therapy was 4 months for patients with low-grade lymphoma and 2 months for high-grade lymphoma. For responding patients (CR + PR), TTP was approximately 10 and 7 months, respectively, for the two groups of lymphomas. Median survival from the start of treatment was 11 months (range 1.3-46.6) for low-grade lymphoma and 3.8 months (range 2.2-17.6) for high-grade lymphoma. Haematological and other toxicities were low and did not cause any major treatment interruptions. Trofosfamide is an interesting and a non-toxic palliative treatment for relapsing malignant lymphomas especially in elderly patients.
authors.affiliation: Department of Oncology, Orebro Medical Center Hospital, Sweden.
authors.forename: M D
authors.initials: MD
authors.lastname: Helsing
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; C003726:trofosfamide